Fig. 2: In vivo assessment of toxicity. | Nature Communications

Fig. 2: In vivo assessment of toxicity.

From: Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance

Fig. 2

a The pharmacokinetics of mProIFNa4-Fc and mIFNa4-Fc were compared in C57BL/6 mice following one intravenous (i.v.) dose at 1 nmol (n = 4 animals). b, c Healthy C57BL/6 J mice were intraperitoneally (i.p.) treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc, every 3 days for 6 times (n = 4 animals). Body weight (b) and survival curve (c) were shown. d–h Healthy C57BL/6 J mice were intraperitoneally (i.p.) treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc, every 3 days for three times (n = 9 animals). Plasma samples were collected 2 days after the last treatment. The levels of IFN-γ (d), IL-6 (e) and MCP-1 (f) were quantified by cytometric bead array (CBA). The levels of ALT (g), AST (h) were determined by UTSW Metabolic Phenotyping Core. i, j C57BL/6 J mice were s.c. inoculated with 5 × 105 B16 cells and i.p. treated with 1 nmol of hIg, mIFNa4-Fc, or mProIFNa4-Fc on day 11 (n = 7 animals). Liver and tumor tissues were harvested 48 h after treatment. Intracellular RNA was extracted for RT-qPCR assay to determine expression levels of MX1 in B16 tumors (i) and livers (j). Data are reported as mean ± s.e.m. Two-tailed t-tests were performed to calculate p-values. Source data are provided as a Source Data file.

Back to article page